Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Sarepta's Elevidys launch remains strong with solid beat, says JPMorgan
03:00pm, Monday, 13'th Jan 2025
Sarepta + Arrowhead +0.18 (+0.97%)
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
12:25pm, Monday, 13'th Jan 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 n
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
11:19am, Tuesday, 07'th Jan 2025
LUND, Sweden , Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Co
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
08:51am, Monday, 06'th Jan 2025
The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential.
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 06'th Jan 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 43rd
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Tuesday, 31'st Dec 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant Date�
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
04:45pm, Friday, 20'th Dec 2024
Japanese drugmaker Nippon Shinyaku infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday.
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
02:25pm, Thursday, 19'th Dec 2024
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundament
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
09:45am, Thursday, 19'th Dec 2024
The phase III EMERGENE study evaluates Sarepta's experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that enrollment and dosing is complete in EMERG
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
10:01am, Tuesday, 17'th Dec 2024
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe
11:20am, Friday, 13'th Dec 2024
New Food and Drug Administration (FDA) guidance on accelerated approval for drugs targeting “serious conditions” appears to be a positive move for rare diseases, analysts at Jefferies believe. The
Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
10:56am, Friday, 13'th Dec 2024
The consensus price target hints at a 48% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning
Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?
06:48am, Monday, 09'th Dec 2024
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Friday, 29'th Nov 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the “Grant Date�
